Shanghai Rightongene Biotechnology バランスシートの健全性
財務の健全性 基準チェック /46
Shanghai Rightongene Biotechnology has a total shareholder equity of CN¥948.1M and total debt of CN¥20.8M, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are CN¥1.0B and CN¥66.9M respectively.
主要情報
2.2%
負債資本比率
CN¥20.77m
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | CN¥224.25m |
| エクイティ | CN¥948.10m |
| 負債合計 | CN¥66.93m |
| 総資産 | CN¥1.02b |
財務の健全性に関する最新情報
更新なし
Recent updates
Shanghai Rightongene Biotechnology Co., Ltd.'s (SHSE:688217) Share Price Boosted 32% But Its Business Prospects Need A Lift Too
Oct 18
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Jul 23Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality
Apr 23財務状況分析
短期負債: 688217's short term assets (CN¥484.9M) exceed its short term liabilities (CN¥39.1M).
長期負債: 688217's short term assets (CN¥484.9M) exceed its long term liabilities (CN¥27.9M).
デット・ツー・エクイティの歴史と分析
負債レベル: 688217 has more cash than its total debt.
負債の削減: 688217's debt to equity ratio has increased from 0.3% to 2.2% over the past 5 years.
債務返済能力: 688217's debt is well covered by operating cash flow (232.5%).
インタレストカバレッジ: Insufficient data to determine if 688217's interest payments on its debt are well covered by EBIT.